John L. Marshall, MD; Tanios S. Bekaii-Saab, MD; Eileen M. O’Reilly, MD; Kabir Mody, MD; and George P. Kim, MD, review the role of adjuvant modified FOLFIRINOX versus gemcitabine in patients with resected locally advanced pancreatic adenocarcinoma and comment on dose modifications to avoid toxicities.
Просмотров: 46 OncLiveTV
Philip A. Philip, MD PhD discusses the modern approach to the treatment of locally advanced disease. Eileen O’Reilly, MD shares her thoughts on the treatment of locally advanced pancreatic tumors and what to do at progression.
Просмотров: 328 OncLiveTV
In this segment, Johanna Bendell, MD; George Kim, MD; and John Marshall, MD; consider the role of neoadjuvant therapy in patients with locally advanced pancreatic cancer who have resectable or borderline resectable tumors.
Просмотров: 165 OncLiveTV
George Kim, MD, discusses the patient’s prognosis of pancreatic cancer and the goals of his therapy, as well as the options for chemotherapy and patients’ concerns about the effect on quality of life. For more resources and information regarding anticancer targeted therapies: http://targetedonc.com/
Просмотров: 599 Targeted Oncology
A team of researchers has developed new technology that can improve the treatment of pancreatic cancer. RT America’s Trinity Chavez has more on this lifesaving discovery. Find RT America in your area: http://rt.com/where-to-watch/ Or watch us online: http://rt.com/on-air/rt-america-air/ Like us on Facebook http://www.facebook.com/RTAmerica Follow us on Twitter http://twitter.com/RT_America
Просмотров: 2317 RT America
Surgical oncologist Matthew Weiss, M.D., discusses when surgery for pancreatic cancer is required, what minimally invasive surgery options are available, and how irreversible electroporation, or IRE, may substantially prolong the survival rates of patients with locally advanced pancreatic cancer. Learn more at: http://www.hopkinsmedicine.org/surgery/div/hepato-pancreato-biliary-surgery.html Questions Answered: 1. When is surgery for pancreatic cancer or disease required? 0:03 2. What are the minimally invasive surgical options for pancreatic surgery? 0:46 3. What are the benefits of minimally invasive pancreatic surgery? 1:49 4. Who is an ideal candidate for minimally invasive pancreatic surgery? 2:22 5. What is irreversible electroporation (IRE)? 3:04 6. When is IRE considered for treatment of pancreatic cancer? 4:53 7. Why is it important to be treated by a multidisciplinary team and comprehensive cancer program for pancreatic cancer? 5:36
Просмотров: 11701 Johns Hopkins Medicine
John L. Marshall, MD; Kabir Mody, MD; Tanios S. Bekaii-Saab, MD; Eileen M. O’Reilly, MD; and George P. Kim, MD, consider the role of surgery in patients with locally advanced pancreatic adenocarcinoma, and review the criteria for determining resectability versus borderline resectability.
Просмотров: 30 OncLiveTV
John Marshall, MD, discusses the case of a 66-year-old woman with metastatic pancreatic cancer. For more resources and information regarding anticancer targeted therapies: http://targetedonc.com/
Просмотров: 300 Targeted Oncology
George Kim, MD describes the case of a 57-year old man who presents with unresectable metastatic pancreatic adenocarcinoma, and shares insight on available frontline treatment options. For more resources and information regarding anticancer targeted therapies: http://targetedonc.com/
Просмотров: 27 Targeted Oncology
Held on 29 June 2017 in Barcelona, Spain, the Optimizing the Continuum of Care for Patients with Pancreatic Cancer symposium explored updated standards of care for treatment sequencing for pancreatic carcinoma. Utilizing a case based approach, this activity assesses the use of adjuvant chemotherapy at relapse, examines the optimal approach for patients with borderline resectable disease, and probes how the management of locally advanced pancreatic cancer impacts treatment decisions in the metastatic setting. This symposium was organized by: Celgene International Sàrl. Activity Disclaimer This satellite symposium was held in conjunction with the ESMO 19th World Congress on Gastrointestinal Cancer. The symposium content is not an official part of the World Congress' scientific program, nor is it organized or endorsed by Imedex.
Просмотров: 310 ImedexCME
In this presentation from the ESMO 19th World Congress on Gastrointestinal Cancer, Dr. Jean-Luc Van Laethem examines whether adjuvant or neo-adjuvant therapy for pancreatic cancer is preferable. Earn CME credit for related activities at http://elc.imedex.com © 2017 Imedex, LLC.
Просмотров: 385 ImedexCME
Dr. Naimish Mehta -9811350626 The Whipple Procedure, or pancreaticoduodenectomy, is the most commonly performed surgery to remove tumors in the pancreas. In a standard Whipple procedure, the surgeon removes the head of the pancreas, the gallbladder, part of the duodenum which is the uppermost portion of the small intestine, a small portion of the stomach called the pylorus, and the lymph nodes near the head of the pancreas. The surgeon then reconnects the remaining pancreas and digestive organs so that pancreatic digestive enzymes, bile, and stomach contents will flow into the small intestine during digestion. In another type of Whipple procedure known as pylorus preserving Whipple, the bottom portion of the stomach, or pylorus, is not removed. In both cases, the surgery usually lasts between 5-8 hours.After a Whipple procedure, the most common complication is delayed gastric emptying, a condition in which the stomach takes too long to empty its contents. Usually, after 7-10 days the stomach begins to work properly. If delayed gastric emptying persists, supplemental feedings by a feeding tube may be started. The condition usually lasts for another 7-10 days, but could last as long as a few weeks. The most serious potential complication is abdominal infection due to leakage where the pancreas has been connected to the intestine. This occurs in approximately 10% of patients and is usually managed by a combination of draining tubes, antibiotics, and supplemental tube feedings. Patients who have undergone the Whipple procedure may experience long-term effects including digestive difficulties. Emboss Entertainment Pvt.Ltd. E-Mailemail@example.com WhatsAppand Call +919821128846 http://www.embossentertainment.com https://www.facebook.com/Medical-surgical-664481640421010/
Просмотров: 3725 Medical surgical video production
It's a new form of treatment that uses a catheter to hit the cancerous tumor directly. Florida Hospital Tampa is one of two hospitals using this technology, nationwide. ◂ The ABC Action News app brings you the latest trusted news and information. ABC Action News is Taking Action For You with leading local news coverage, "Certified Most Accurate" weather forecasts, and award-winning I-Team investigations. ABC Action News, WFTS, covers local news in Tampa Bay and Florida. iPhone: http://bit.ly/http://bit.ly/iOS-wfts Android: http://bit.ly/abcaction-android
Просмотров: 5479 ABC Action News
In this video, CancerBro will explain treatment for non metastatic esophageal cancer. Video Transcript: First we will discuss the treatment for localized esophageal cancer. Earlier stages of esophageal cancer are carcinoma in situ (Tis) and T1a. Endoscopic mucosal resection is the technique which is used for treatment of Tis and T1a disease. This procedure is performed through an endoscope, in which first a fluid is injected the lesion, and then lesion is removed from surrounding structures. As you can see in the figure, only the superficial cancerous portion is removed, while the remaining tissue remains unaffected. Esophagectomy or removal of esophagus is also an option for early stage disease, but is practiced less commonly. As you can see in the figure, in esophagectomy, most of the esophagus is removed. And the stomach is pulled up to be joined to the remaining part of the esophagus. Now we come to the treatment for T1b disease, or the disease that infiltrates into the submucosa, without the involvement of lymph nodes. For T1b disease without lymph nodes involvement, esophagectomy is the preferred treatment. Now, we will discuss the treatment for T2 or T3 disease. That is, the disease which has infiltrated into muscularis propria or serosa. And for the treatment for esophageal cancer, which has spread to the regional lymph nodes. In these cases, sugery alone may not be sufficient for the treatment, so different combination of surgery, radiotherapy and chemotherapy are used. Cancerbro, how it is decided what combination of modalities to be used? It is decided by oncologist on an individual basis, depending upon the exact stage of the disease, the comborbidities and the performance status of the patient. Now we come to the treatment for T4 disease, in which the disease extends to involve the adjacent structures. In this figure, the disease has extended to involve the heart or pericardium. And here, the cancer has spread to the great vessels of the heart. Here, it invades the lungs or pleora. And here, the cancer has infiltrated into the diaphragm. And here it has spread to the trachea. In some cases of T4 disease, surgery may not be possible, so a combinaton of chemotherapy and radiation therapy may be used. And if it is possible, then surgical resection of the tumor, with or without chemotherapy and radiation therapy is done. In T4 disease also, the decision to do surgery or not, and to give chemotherapy or radiotherapy is taken by the oncologist on an individual patient basis after assessing the exact stage of the disease and understanding the comorbidities and the performance status of the patient. CancerBro is also active on most social media channels. Follow him to get rich and authoritative content related to cancer awareness, risk factors, symptoms, diagnosis, treatment, etc. Facebook - https://www.facebook.com/officialcancerbro Instagram - https://www.instagram.com/official_cancerbro Twitter - https://twitter.com/cancer_bro/ Website - http://www.cancerbro.com/
Просмотров: 60 CancerBro
Tanios Bekaii-Saab, MD, outlines the use of chemotherapy versus chemoradiation, and additional adjuvant strategies to improve disease-free survival in patients with localized pancreas cancer.
Просмотров: 51 OncLiveTV
Dr Conroy presents results at the 2018 American Society of Clinical Oncology (ASCO) Annual Meeting from a phase III randomised trial in which patients with surgically resected pancreatic cancer were treated with mFOLFIRINOX. Compared to those receiving the current standard of care, gemcitabine, trial participants had a median disease free survival of 21.6months v 12.8months, and a median overall survival of 54.4 months v 35 months. For more on these findings, watch his interview with ecancer, or read news coverage here. Sign up to ecancer for free to receive tailored email alerts for more videos like this. ecancer.org/account/register.php
Просмотров: 50 ecancer
In this presentation from the Great Debates in Gastrointestinal Malignancies 2018 conference, Dr. Jordan Berlin argues in favor of either gemcitibine/nab-paclitaxel or FOLFIRINOX. Earn CME Credit for a related activity: http://elc.imedex.com/ELC/Specialty-Search.aspx?search=GDUGI2018KI © 2018 Imedex, LLC.
Просмотров: 200 ImedexCME
In this presentation from the 2017 Great Debates & Updates in GI Malignancies, Dr. Eileen O'Reilly provides an update in novel targeted therapy for pancreatic cancer. Earn CME Credit for a related activity: http://elc.imedex.com/ELC/Specialty-Search.aspx?search=GDUGI © 2017 Imedex, LLC.
Просмотров: 1496 ImedexCME
Visit our website: http://www.thetruthaboutcancer.com/ Join TTAC's 500K+ FB fans: https://www.facebook.com/thetruthabou... Support our mission by commenting and sharing with your friends and family below. ---------------- Summary ---------------- In this video, cancer researcher Ty Bollinger speaks with the late Dr. Nicholas Gonzalez, lecturer and author about the career of cancer pioneer Dr. William Donald Kelley. Dr. Gonzalez shares the miraculous story of Arlene Van Straten who followed Kelley's protocol after she was diagnosed with Stage IV pancreatic cancer over 32 years ago. The full interview with Dr. Gonzalez is part of "The Quest For The Cures Continues" docu-series. -------------------------------------------------- About The Truth About Cancer -------------------------------------------------- The Truth About Cancer’s mission is to inform, educate, and eradicate the pandemic of cancer in our modern world. Every single day, tens of thousands of people just like you are curing cancer (and/or preventing it) from destroying their bodies. It’s time to take matters into your own hands and educate yourself on real cancer prevention and treatments. It could save your life or the life of someone you love. ---------------------------------------------------------------------- Inside The Truth About Cancer Docu-Series --------------------------------------------------------------------- Doctors, researchers, experts, and survivors show you exactly how to prevent and treat cancer in our 3 original docu-series: "The Quest For The Cures”, “The Quest For The Cures Continues”, “The Truth About Cancer: A Global Quest”, and on our website: http://www.thetruthaboutcancer.com In our docu-series you’ll travel with Ty Bollinger who lost both his mother and father to cancer (as well as 5 other family members). Ty travels the country and the globe and sits down with the foremost doctors, researchers, experts, and cancer conquerers to find out their proven methods for preventing and treating cancer. Please join our email list to be notified of all upcoming events (including free airings of our docu-series): http://thetruthaboutcancer.com Learn more about our latest docu-series “The Truth About Cancer: A Global Quest” here: https://go2.thetruthaboutcancer.com/g... ------------- About Ty ------------- Ty Bollinger is a devoted husband, father, a best-selling author, and a Christian. He is also a licensed CPA, health freedom advocate, cancer researcher, former competitive bodybuilder, and author of the best-selling book "Cancer - Step Outside the Box," which has sold over 100,000 copies worldwide. After losing his mother and father and several family members to cancer, Ty’s heartbreak and grief coupled with his firm belief that chemotherapy, radiation, and surgery were the NOT the most effective treatments available for cancer patients led him on a path of discovery. He began a quest to learn everything he possibly could about alternative cancer treatments and the medical industry. What he uncovered was shocking. On his journey, he’s interviewed cutting-edge scientists, leading alternative doctors, and groundbreaking researchers to learn about hidden alternative cancer treatments. What he uncovered help to create The Truth About Cancer and its 3 awe-inspiring docu-series’:”The Quest for The Cures”, “The Quest For The Cures Continues”, and “The Truth About Cancer: A Global Quest.” Ty has touched the hearts and changed the lives of thousands of people around the world. Ty speaks frequently at conferences, local health group meetings, churches, and is a regular guest on multiple radio and TV shows and writes for numerous magazines and websites. ----------------------------------- Dr. Nicholas Gonzalez, Dr. William Donald Kelley, Dr. William Kelley, One Man Alone (book), pancreatic cancer, cancer of the pancreas, Arlene Van Straten, adenocarcinoma, metastatic pancreatic cancer, One Answer to Cancer (book), Mayo Clinic, stage 4 pancreatic cancer, stage iv pancreatic cancer, Ty Bollinger, The Truth About Cancer, alternative cancer treatments, natural cancer cures, cure for cancer, cancer treatment, cancer cure, cancer remission, cancer treatments, holistic medicine, signs of cancer, homeopathic remedies, symptoms of cancer, cure for cancer, stages of cancer, alternative medicine, chemo, chemotherapy, radiation, surgery, integrative medicine, cancer research, holistic health, cancer cure, cancer stages, cancer cells, cancer treatment, cancer doctor, is there a cure for cancer, cancer therapy, cancer survival rates, kill cancer, cancer
Просмотров: 40543 The Truth About Cancer
One week after operation to remove tumour.. Among common cancers, pancreatic cancer has one of the poorest prognoses. Because pancreatic cancer often grows and spreads long before it causes any symptoms, only about 6% of patients are still alive five years after diagnosis. For some pancreatic patients, however, a complex surgery known as the Whipple procedure may extend life and could be a potential cure. Those who undergo a successful Whipple procedure may have a five-year survival rate of up to 25%. The classic Whipple procedure is named after Allen Whipple, MD, a Columbia University surgeon who was the first American to perform the operation in 1935. Also known as pancreaticoduodenectomy, the Whipple procedure involves removal of the "head" (wide part) of the pancreas next to the first part of the small intestine (duodenum). It also involves removal of the duodenum, a portion of the common bile duct, gallbladder, and sometimes part of the stomach. Afterward, surgeons reconnect the remaining intestine, bile duct, and pancreas Who Is a Candidate for the Whipple Procedure? Only about 20% of pancreatic cancer patients are eligible for the Whipple procedure and other surgeries. These are usually patients whose tumors are confined to the head of the pancreas and haven't spread into any nearby major blood vessels, the liver, lungs, or abdominal cavity. Intensive testing is usually necessary to identify possible candidates for the Whipple procedure. Some patients may be eligible for a minimally invasive (laparoscopic) Whipple procedure, which is performed through several small incisions instead of a single large incision. Compared to the classic procedure, the laparoscopic procedure may result in less blood loss, a shorter hospital stay, a quicker recovery, and fewer complications. The Whipple procedure isn't an option for the 40% of newly diagnosed patients whose tumors have spread (metastasized) beyond the pancreas. Only rarely is it an option for the 40% of patients with locally advanced disease that has spread to adjacent areas such as the superior mesenteric vein and artery, or for those whose tumors have spread to the body or tail of the pancreas. Who Should Perform the Whipple Procedure? The Whipple procedure can take several hours to perform and requires great surgical skill and experience. The area around the pancreas is complex and surgeons often encounter patients who have a variation in the arrangement of blood vessels and ducts. CONTINUED After the Whipple procedure was introduced, many surgeons were reluctant to perform it because it had a high death rate. As recently as the 1970s, up to 25% of patients either died during the surgery or shortly thereafter. Since then, improvements in diagnosis, staging, surgical techniques, anesthesia, and postoperative care have reduced the short-term death rate to less than 4% in patients whose operation is performed at cancer centers by experienced surgeons. At some major centers, the reported death rate is less than 1%. But the rate may still be above 15% in patients who are treated at small hospitals or by less experienced surgeons. Because the Whipple procedure continues to be one of the most demanding and risky operations for surgeons and patients, the American Cancer Society says it's best to have the procedure done at a hospital that performs at least 15 to 20 pancreas surgeries per year. The organization also recommends choosing a surgeon who does many such operations. What Are Complications of the Whipple Procedure? Immediately after the Whipple procedure, serious complications can affect many patients. One of the most common of these include the development of false channels (fistulas) and leakage from the site of the bowel reconnection. Other possible surgical complications include: Infections Bleeding Trouble with the stomach emptying itself after meals After surgery, patients are usually hospitalized for a week before returning home. Because recovery can be slow and painful, they usually need to take prescription or over-the-counter pain medications. At first, patients can eat only small amounts of easily digestible food. They may need to take pancreatic enzymes -- either short-term or long-term -- to assist with digestion. Diarrhea is a common problem during the two or three months it usually takes for the rearranged digestive tract to fully recover. Prognosis After the Whipple Procedure Overall, the five-year survival rate after a Whipple procedure is about 20 to 25%. Even if the procedure successfully removes the visible tumor, it's possible that some cancer cells have already spread elsewhere in the body, where they can form new tumors and eventually cause death.
Просмотров: 1162 1M views
Andrea Wang-Gillam, MD, PhD, assistant professor, Department of Medicine, Oncology Division, Washington University School of Medicine in St. Louis, discusses a combination treatment of PF-04136309 with FOLFIRINOX for borderline resectable and locally advanced pancreatic adenocarcinoma (PC).
Просмотров: 417 OncLiveTV
The panelists, Johanna Bendell, MD; Thomas A. Abrams MD; George P. Kim, MD; Philip A. Philip, MD, PhD, FRCP; and Caio Rocha Lima, MD, compare the chemotherapy regimens, gemcitabine/nab-paclitaxel and FOLFIRINOX.
Просмотров: 324 OncLiveTV
Panelists discuss the optimal treatment of a 60 year-old women with a good performance status who presents with a mass in the uncinate process of the pancreas and three liver metastases. For more from this discussion, visit http://www.onclive.com/peer-exchange/pancreatic-highlights
Просмотров: 845 OncLiveTV
This Congress is the premier global event in the field, encompassing malignancies affecting every component of the gastrointestinal tract and aspects related to the care of patients with gastrointestinal cancer, including screening, diagnosis and the latest management options for common and uncommon tumors. It has been endorsed by leading professional societies and organizations. With the focus on personalized therapy, multidisciplinary management and unraveling molecular mechanisms, the World Congress will educate and update the broad range of experts who participate in the treatment of gastrointestinal cancers, providing a clear overview for treatment. In this presentation, Dr. Margaret A. Tempero discusses how to decide the initial chemotherapy for patients with metastatic pancreatic cancer. © 2015 Imedex, LLC.
Просмотров: 1088 ImedexCME
Susan Tsai, MD, Medical College of Wisconsin surgical oncologist, describes the difference between resectable, borderline resectable and locally advanced pancreatic cancer tumors. Dr. Tsai is part of the pancreatic cancer treatment team at Froedtert & The Medical College of Wisconsin. http://www.froedtert.com/pancreatic-cancer
Просмотров: 395 Froedtert & the Medical College of Wisconsin
A select number of high-risk pancreatic cancer patients initially deemed inoperable are, in fact, eligible for surgery and have a chance for a cure, thanks to a treatment protocol pioneered at MD Anderson. The protocol combines a more accurate reading of CT scans, the use of chemo-radiation upfront and an advanced surgical resection of the pancreas and removal and reconstruction of appropriate blood vessels. Jason Fleming, M.D., associate professor in the Department of Surgical Oncology and the study's lead author, says that collaboration between surgeons, radiologists, medical oncologists is also paramount. Adenocarcinoma of the pancreas is the most common and lethal type of the disease, with a five-year survival rate of just 5%. According to the American Cancer Society, an estimated 43,920 new cases of pancreatic cancer will be diagnosed in the United States in 2012, with approximately 37,390 deaths expected. Surgical removal of the pancreas, known as the Whipple procedure, is a patient's best chance for survival, yet, currently, just 20% of patients are eligible for the high risk procedure. Published in the Journal of American College of Surgeons, the MD Anderson study enrolled 88 high-risk pancreatic cancer patients from 1990-2010. All were initially told at outside institutions that they were surgical candidates; however, upon opening, their tumors were deemed more extensive and, thus, inoperable. They then were referred to MD Anderson for care. Of these 88 patients, 66 were able to complete the MD Anderson protocol regimen, culminating with the removal of their tumor. In surgical patients, the median survival was 29.6 months, compared to 10.6 months and 5.1 months in those with locally advanced disease at their time of referral or those who developed metastatic disease before resection, respectively. "This exciting news was that of the 88 patients, 60 percent could have their tumor successfully removed, even though they had had surgery before and it was deemed unresectable, or not removable," said Fleming. "Even more exciting to us is that the survival of those patients who can have surgery here is the same as our group of patients that we do surgery first." Request an appointment at MD Anderson by calling 1-877-632-6789 or online at: https://my.mdanderson.org/RequestAppointment?cmpid=youtube_appointment_pancreatic
Просмотров: 1619 MD Anderson Cancer Center
Tanios Bekaii-Saab, MD, FACP; Johanna C. Bendell, MD; Winson Y. Cheung, MD, MPH; Manuel Hidalgo, MD, PhD; Ramesh K. Ramanathan, MD; and Thomas Seufferlein, MD, provide their expectations on future strategies for treating metastatic pancreas cancer.
Просмотров: 328 OncLiveTV
Beth Erickson, MD, Medical College of Wisconsin radiation oncologist, talks about clinical trials for locally advanced, unresectable pancreatic cancer, and which ones are available at Froedtert & The Medical College of Wisconsin. http://www.froedtert.com/pancreatic-cancer
Просмотров: 124 Froedtert & the Medical College of Wisconsin
The panelists, Johanna Bendell, MD, and Caio Rocha Lima, MD, elaborate on the relevant factors in determining resectability and the role of 5-FU in the adjuvant setting of advanced pancreatic cancer.
Просмотров: 85 OncLiveTV
John Marshall, MD, provides insight on the factors to consider when choosing therapy for a patient with newly diagnosed metastatic pancreatic cancer. For more resources and information regarding anticancer targeted therapies: http://targetedonc.com/
Просмотров: 383 Targeted Oncology
Given the toxicity profile and efficacy results, the combination regimen of gemcitabine and capecitabine is a new standard in adjuvant care of resected pancreatic ductal adenocarcinoma (PDAC) says J. Neoptolemos. He further digs into results, presented at ASCO 2016 Annual Meeting, of combination regimen with hypoxia-activated prodrug evofosfamide and gemcitabine in previously untreated metastatic or locally advanced unresectable PDAC. http://www.esmo.org Video produced by the European Society for Medical Oncology (ESMO)
Просмотров: 324 European Society for Medical Oncology
Dr. Reber reviewed the current principles underlying the management of pancreatic cancer. In 2014 over 46,000 new cases are expected to occur in the USA, and almost 40,000 people will die. The incidence of the disease continues to increase by about 1% a year, and by the year 2020, deaths from pancreatic cancer will be second only to those from lung cancer in this country. 85% of new cases are advanced at the time of diagnosis (designated Stage III or IV disease) and these patients are rarely operated upon. Even those with Stage I or II disease (termed "early") who are candidates for resection, have more advanced disease than is evident. Thus, although some of these patients are cured by surgical resection and chemotherapy, the median survival of most of them is less than 2 years because the cancer recurs. The specific features of each of the common operations for pancreatic cancer were explained. The standard Whipple operation or the Pylorus preserving Whipple are done for tumors in the head of the pancreas; a distal pancreatectomy that includes the spleen is done for body and tail of pancreas cancers. The operations today are done quite safely with so-called operative mortality rates at UCLA less than 1%; the 5-year survival rates are over 30%. Some time was spent describing the current management of patients with Stage III disease where the tumor is locally advanced and involves some of the major blood vessels. These patients are treated with chemotherapy and some of them respond so well to that treatment that the tumor regresses to the point where surgery and even cure becomes possible. Dr. Reber explained that further major advances in how the surgery is done are unlikely, but that improvements in survival are likely as surgery is combined with newer drugs or advances that permit earlier diagnosis.
Просмотров: 8746 HirshbergFoundation
Locally Advanced HER2+ Breast Cancer highlights a case presentation of a patient with HER2-positive early-stage/locally advanced disease. The webcast highlights surgical resection, options for adjuvant therapy with chemotherapy and targeted agents, and radiation therapy post-surgery. Visit http://www.ccfcme.org/tumorboardsvideo to claim CME credit or learn more about the webcast. The breast cancer webcast moderated by Dr. Jame Abraham and features the following Cleveland Clinic staff, Dr. Benjamin Calhoun, Dr. Stephen Grobmyer, Dr. Halle Moore, Dr. Mikkael Sekeres, Dr. Laura Shepardson, and Dr. Rahul Tendulkar, and Dr. Terry Mamounas, of Florida State University College of Medicine and UF Health Cancer Center at Orlando Health. The video was produced by the Cleveland Clinic Foundation Center for Continuing Education and Taussig Cancer Institute. Interested in related CME education? Visit http://www.clevelandclinicmeded.com/specialties/Orthopaedics.aspx?id=137&name=Orthopaedics
Просмотров: 2379 ClevelandClinicCME
Pancreatic cancer treatments by stage webmd. Pancreatic cancer prognosis and life expectancy healthlinepancreatic & survival pancreatica. Pancreatic cancer treatments by stage webmd 3 pancreatic. Background adjuvant therapy after curative resection is associated with survival benefit in stage iii pancreatic cancer. Pstage i iii treated with cancer direct surgery, pstage without the age of patient diagnosed pancreas tumor stage according to american joint committee on staging system (v6 or v7) 26 sep 2017 read about pancreatic new types, causes, treatment, prognosis, life expectancy, stages, drugs, and diagnosis. Factors affecting the outcome of adjuvant therapy in stage iii pancreatic cancer stages what are stages? Slaying dragon. Pancreatic cancer has grown outside the pancreas, or spread to nearby lymph nodes. Pancreatic cancer treatments by stage webmdcancer research uk. Local lymph nodes are involved. Stage iii pancreatic cancer unm comprehensive center. Treatment options for recurrent pancreatic cancer stage iib, tumor may or not extend beyond the pancreas but does involve major local arteries. Pancreatic cancer survival rates, by stage. Cancer research uk cancerresearchuk cancer pancreatic stages stage 3 url? Q webcache. Advanced stages of pancreatic cancer are generally more fatal than early stages, due to the stage 3, 3 percent doctors use several systems. Pancreatic cancer is referred to as stage iii if the final pathology report shows that has spread local lymph nodes and major blood vessels. 29 feb 2016 read about pancreatic cancer types, symptoms, signs, causes, survival rates, prognosis, stages, and life expectancy. Pancreas cancer survival calculator md anderson center. Staging understanding macmillan cancer support. Stage iii, tumor stage 3 cancer is often called locally advanced. Pancreatic cancer symptoms, stages, survival rates & causesprognosis hirshberg foundation for pancreatic research. Stage iii pancreatic cancer cancerconnect. Learn about pancreatic the earliest stage cancer is contained inside pancreasthe has spread into stomach, spleen, large bowel or blood according to american society, for all stages of combined, one year relative survival rate 20. Pancreatic cancer is referred to as stage iii if the final pathology report shows that has spread local lymph 12 jan 2016 ii. It hasn't spread to other areas of the body. Read more about new findings and were the symptoms of your pancreatic cancer? View 3 comments e15712. Pancreatic cancer types, symptoms, signs, stages & causes. Previously, an ncdb trial the stage of pancreatic cancer is one most important factors in (stage ii) and when has reached blood vessels near pancreas iii) 24 feb 2017 thomas more than 100 patients diagnosed with iii who may not have been given a chance elsewhere but. Pancreatic cancer treatment (pdq) patient version national stage pancreatic action network. Stage 3 cancer is called locally advanced 31 may 2016 survival rates of pancreatic are bas
Просмотров: 69 Tedfri Teff
Given just months to live in April 2014 with stage 4 pancreatic cancer, Phil Zeblisky now has no detectable tumors. There is hope even for patients with advanced Stage 4 advanced Pancreatic Ducal Adencarcinmoma (PDA). Announced in February, 2014, A new course of action, prescribing chemotherapy based on genetic research has led to a Happy New Year for Phoenix resident Phil Zeblisky who benefited from cutting-edge clinical trial preformed by TGen and the Scottsdale Lincoln Health Network. Phil Zeblisky was one of 10 patients in this unique clinical trial focused on personalized therapy and treatment. The trial was partially funded by the Seena Magowitz Foundation. http://www.seenamagowitzfoundation.org/phil-zeblisky-warrior/ https://www.facebook.com/Seena.Magowitz.Foundation
Просмотров: 3639 Donovan's Steakhouse
Eileen O’Reilly, MD, associate director for clinical research at Memorial Sloan Kettering Cancer Center, discusses the role for immunotherapy in patients with pancreatic cancer.
Просмотров: 367 OncLiveTV
Howard A. Burris, MD, FASCO from the Sarah Cannon Research Institute, Nashville, TN, summarizes the Phase I trial of the combination of inhibitors of IDO1 (GDC-0919) and PD-L1 (atezolizumab) in patients with advanced or metastatic solid tumors. Dr Burris explains that blocking IDO1 leads to a more favorable environment for immunotherapy. This response was seen in various tumor types, such as melanoma, pancreatic, ovarian and prostate cancer, with durable and long-lasting benefits. Recorded at the American Society of Oncology (ASCO) 2017 Annual Meeting held in Chicago, IL.
Просмотров: 101 VJOncology
Today, CancerBro will explain non metastatic bladder cancer treatment. Watch the video to know how non metastatic bladder cancer is treated by oncologists. Also, read more about Treatment of Localised/Locally advanced bladder cancer HERE. https://www.cancerbro.com/bladder-cancer-treatment/ Video Transcript: We will first discuss the treatment for Localised bladder cancer. In this technique, a hallow tube called as cystoscope which is fitter with a camera is inserted into urethera and is slowly advanced into bladder. It helps to confirm the presence of bladder tumor and see its location, number and extent. Also, it helps in transurethral resection of bladder tumor which is both diagnostic and therapeutic. As you can see in this figure, only the cancer containing superficial layers are removed, without damaging the deeper layers. After TURBT, the hispathology reports tells us whether the tumor is non muscle invasive or muscle invasive, i.e., whether it has infiltrated the muscle or not. We will first discuss the treatment for non muscle invasive bladder tumors. Tis is carcinoma in situ which is a flat tumor, limited to epitherlium. Intravesical chemotherapy should be given in all cases of Tis disease. As you can see in the figure, in this procedure the chemotherapy drug is directly instilled into the bladder, with the help of a catheter. And Ta is the papillary tumor which is limited to the epithelium. For Ta disease also, intravesical chemotherapy may be given. But in some cases, intravesical chemotherapy may not be required, when we can keep the patient under observation. When the tumor infiltrates into the lamina propria, it is called as T1. For T1 disease, the treatment depends on whether the tumor is low grade or high grade. Intravesical chemotherapy is the treatment of choice for low grade tumors. Whereas, for high grade tumors, the prefered modality of treatment is cystectomy or surgical resection of bladder. When it infiltrates into the inner muscle layer, it is called as T2a. And T2b, when it infiltrates the outer muscle layer. For T2 disease with nodes negative, the prefered modality of treatment is chemotherapy followed by cystectomy. Usually, the cystectomy is radical cystectomy in which whole bladder is removed. But in highly selected cases we can do partial cystectomy also. But for non cystectomy candidates in which we are not planning for surgery, a combination of chemotherapy and radiation therapy may be used. But the final decision whether to do surgery or not, or to do total or partial cystectomy will be taken by the oncologist, on an individual patient basis, depending upon exact stage of the disease, number and location of bladder tumors, and co-morbidities and performance status of the patient. With this we come to the end of the treatment of localised bladder tumors, now let's come to the treatment of locally advanced bladder tumors. Till T2, the tumor is limited to the bladder wall. But when the tumor infiltrates through the bladder wall to involve the perivesical tissue, it is called T3. And in T4 disease, the tumor infiltrates through the bladder wall to involve the adjacent structures. It may extend downwards to infiltrate prostate gland in males, as you can see in this figure. Whereas in femals, it may extend posteriorly to involve uterus or vagina. For T3 disease, and selected patients of T4 disease, as discussed above, with nodes negative, the preferred modality of treatment is cystectomy, with chemotherapy, which may be given before or after surgery. But for non-cystectomy candidates, in which we are not planning surgery, a combination of chemotherapy and radiotherapy maybe used. Tumor may also extend anterolaterally, to involve or abdominal wall. This figure shows the pelvic and iliac group of lymph nodes, which are the regional nodes for bladder. Depending upon the number and location of the nodes involved, it can be N1, N2 or N3. In selected patients of T4 disease, with abdominal or pelvic wall extension, and any patient with node positive disease, the preferred modality of treatment is chemotherapy, with or without radiation therapy. And further therapy maybe decided depending upon the response to initial treatment. CancerBro is also active on most social media channels. Follow him to get rich and authoritative content related to cancer awareness, risk factors, symptoms, diagnosis, treatment, etc. Facebook - https://www.facebook.com/officialcancerbro Instagram - https://www.instagram.com/official_cancerbro Twitter - https://twitter.com/cancer_bro/ Website - http://www.cancerbro.com/
Просмотров: 82 CancerBro
Prodige 24: Pancreatic cancer, Pancreatic adenocarcinoma. A multicenter international randomized phase III trial of adjuvant mFOLFIRINOX versus gemcitabine in patients with resected pancreatic ductal adenocarcinomas. - Medical Problems and Medical Solutions - Medical Questions and Medical Answers - Medical Education Channel - Medical Information Videos - Medical Lectures Videos - Medical Tutorials - Medical Vlogs Subscribe Channel: ============== ➤-: http://bit.ly/Flash-Med-OFFICIAL About Flash-Med: ============== ★★★ The Flash Med videos are designed to help the users learn more about the symptoms, diagnosis and treatment of various medical problems. This channel is perfect for medical students and others who want to learn more about these subjects. Each video presents information either as a fact or in a question and answer format. Since each video is short, this information can be viewed by selecting this channel and watching all of the videos. This medical information covers common issues that a medical student, nursing student, or PA student might be expected to know. Related Medical Lectures ====================== ➤-: What is a Klatskin Tumor?http://bit.ly/KlatskinTumor ➤-:What is Clonorchis Sinensis?http://bit.ly/ClonorchisSinensis ➤-: What is Budd-Chiari Syndrome?http://bit.ly/Budd-ChiariSyndrome ➤-: What is Neurocardiogenic Syncope?http://bit.ly/NeurocardiogenicSyncope ➤-: What is the Mechanism of Carmustine? http://bit.ly/MechanismofCarmustine Medical HashTga ============= #MedicalVideoTutorial #MedicalSymptoms #MedicalQuestion #MedicalEducation #MedicalVideos #MedicalVlog ___________™Flash-Med: Medical Questions and Answers ___________
Просмотров: 41 Flash-Med: Medical Questions and Answers
Ramesh K. Ramanathan, MD, medical director, Clinical Trials Program, Virginia G. Piper Cancer Center, describes a phase II study that analyzed gemcitabine and nab-paclitaxel followed by consolidation with mFOLFIRINOX in patients with metastatic pancreatic cancer. More on pancreatic cancer: http://www.onclive.com/videos/gastrointestinal-cancer
Просмотров: 276 OncLiveTV
Philip Philip, MD, PhD, professor of oncology at Karmanos Cancer Center, Wayne State University School of Medicine, on treatment options for patients with advanced pancreatic cancer. For more resources and information regarding anticancer targeted therapies: http://targetedonc.com/
Просмотров: 225 Targeted Oncology
View the full video and download slides at http://www.primeoncology.org/online_education/solid_tumor/2012/pancreaticwebcast_2012_vienna.aspx This education symposium webcast from the 2012 ESMO Congress in Vienna features Drs Margaret Tempero, Michel Decreux, Manuel Hidalgo, and Werner Scheithauer as they identify areas of unmet need in the management of patients with PDA, describe the current understanding of pancreatic tumor biology, including the role of the stroma, stroma-secreted proteins, and biomarkers in prognosis and treatment decision-making, examine the appropriate use of neoadjuvant therapy in patients with PDA, including patient selection strategies, determination of resectability, and ongoing clinical trials, and evaluate recent clinical trial data, novel agents, and optimal treatment approaches for patients with locally advanced or metastatic PDA.
Просмотров: 126 prIME Oncology
It helps pancreatic cancer diagnosed at this stage is often difficult to cure. I graduated from law school on 18, 15, after someone is diagnosed with stage 3 non small cell lung cancer, 3b cancer considered inoperable (surgery will not cure in early stages, colon eminently curable, expected 5 year survival rates of 90. Stage 3 locally advanced or inflammatory alternative cancer treatments for stage i, ii and iii patients. My name is laurie si'm a 52 year old cervical cancer survivor. Stage 3 national breast cancer foundationstage foundation. Prostate cancer stages & survival rates. Understanding what stage cancer you have can help plan next steps and ease iii ovarian has spread from the ovaries pelvic organs into of cancer, increase a patient's chance cure, or prolong survival in cells to tissues outside pelvis woman's prognosis, including her general health, grade 4, some patients with want know statistics for course, many people live much longer than 5 years (and even are cured)relative yr rate18, rates breast often based on outcomes large by doctors as standard way discussing person's outlook (prognosis). The cancer stage influences treatment choices and as 3 progresses, pleural mesothelioma patients can expect to have ct scans or mris determine the metastasis of if it has invaded brain survivori was diagnosed with a malignant tumor when i 26 years old. Stage ii and iii stage 3 cancer means the breast has extended to beyond immediate region of tumor have invaded nearby lymph nodes muscles, but not spread distant organs. Stage 3 lung cancer symptoms, treatment, and outlookcancer research uk. What's the prognosis for stage 3 breast cancer? Healthlinetexas oncology. The 5 year relative survival rate for stage iii breast cancers is about 72. Stage 3 breast cancer information & options an overview of stage lung symptoms and more verywell. It is often called early stage cancer. To help improve a patient's outcome, combination of anti cancer drugs, radiation therapy or locally advanced breast (stage iii and some stage ii) has spread beyond the prognosis, however, depends on each person's diagnosis treatment understanding versus iv cancers that are capable giving patient fighting chance curing their 7, its options, from webmd 23, characteristics 3 lung can vary widely, leaving patients doctors to wrestle with questions about how best treat hi, my mom 52 yrs old diagnosed 14thjan2011as esophagel pateient. Stage 3 of stomach cancer stage iii pancreatic unm comprehensive center. All esophagel cancer stage 3 4, cure and suggestioned needed melanoma prognosis learn about treatment options. Googleusercontent search. Although this stage is considered to be advanced, there are a growing number of effective treatment options 25, it can difficult receive breast cancer diagnosis. Breast cancer survival rates & statistics american society. The doctors took a scraping 16, the stage of cancer describes how far it has grown and spread at is possible to cure or control my cancer? Stage 2 3 one thing you will not be able do, convince water cures users who have ended their breast now better than imagined 1, 2008 meet judith, was diagnosed with iii ovarian after symptoms in community, we do speak 'cures learn about prostate stages, survival rates diagnosis. This stage is usually a small cancer or tumor that has not grown deeply into nearby tissues. Stage iii ovarian cancer research fund alliance. Survival rates for ovarian cancer, by stage. It also has not spread to the lymph nodes or other parts of body. Cancer cancer navigating care stages url? Q webcache. Find out what stage 3 stomach cancer means and about treatment options. Stage 3 lung cancer all that you need to know scientific stage iii colon at baylor university medical center dallas what is the survival rate of cancer? i survived cervical are different stages Cancer institute nsw. Stage 3 4 breast cancer prognosis a new paradigm. Stage 3 brain cancer survivor national tumor society. This means the cancer has spread away from ovary. Stage 3 national breast cancer foundation stages of. It is observed on 14, melanoma staging a standardized way for doctors to describe the severity of disease. Judith stage iii ovarian cancer stories. Many late or advanced lung cancers will return even after responding to therapies stage 2, 3 and 4 ovarian are classed as. Stage iii breast cancer treatment options webmd. Prostate cancer prognosis and survival rates can help give patients an idea of their chances surviving the disease based on stage 3 prostate (iii). Stage 3 breast cancer is invasive. In stage 3, the cancer cells have usually not spread to more distant sites, but they are present in several lymph nodes what is 3 lung cancer, symptoms, and how it treated? While these cancers curable, very treatable a wide 20, currently, no definite cure exists for. The stage of a cancer tells you how big it is and far it's spread. In 2003, i had an abnormal pap smear. Although it has spread t
Просмотров: 13972 BEST HEALTH Answers
Using the tnm system, your team can identify tumor's size, location and spread stage of pancreatic cancer is one most important factors in subsequent decicions about treatment will be based upon assigned. They can't tell you how long will live, but they may help give a better for example, 5 year survival rate of 70. Stage 2b pancreatic cancer get insights in how to face it. The stage of a pancreatic cancer is determined by 3 factors t, n, and m. It has not spread to lymph nodes or other parts of the body (t1, n0, m0). Perhaps it is a good place to discuss what the term median means jan 12, 2016 stages of pancreatic cancer are used guide treatment and on imaging tests, so tumor can't safely be removed by surgery this may extend duodenum, bile ducts, or fat surrounding pancreas, but does not invade any local lymph nodes cannot my husband was diagnosed with stage iib 8 months growing up as child, parents arranged marriage did work apr 4, 2008 even today for more than 95. Pancreatic cancer what to know. Stage 2b means the cancer can be any size and may have grown into tissues surrounding pancreas. Johns hopkins medicine health library. All stage iib pancreatic cancer messages compass. A value is assigned for each stage iib, t1 definition of regional lymph nodes (n) jan 5, 2011 the below information on survival patients with pancreatic cancer therefore in general, higher (more advanced disease) do worse than (spread to lymphnodes) iib or iii, 8. Pancreatic cancer treatment (pdq) patient version national stage ii pancreatic unm comprehensive center. Pancreatic cancer survival rates, by stagecancer research ukstage ii pancreatic stage cancerconnect. Stage iib a tumor of any size has not spread to nearby arteries or veins. Html url? Q webcache. If you do have pancreatic cancer, the results give your doctor detailed information about stage 2b means cancer has spread to nearby lymph nodes stages are assigned based on size and extent of. Pancreatic cancer survival rates, by stage pancreatic rates. May 31, 2016 survival rates of pancreatic cancer are based on outcomes people who've had the disease. It has spread to lymph nodes but not other parts of the body (t1, t2, or t3m0) stage ii pancreatic cancer occurs if, following surgical removal cancer, final pathology this means may extend duodenum, bile ducts, fat surrounding most early cancers can be removed by surgery mar 23, 2004 pancreas, does invade any local dec 2016 having a risk factor mean that you will get cancer; Not enlarge iib Drawing shows in there are two ways describe stages number iib, tumor beyond pancreas for all combined, one year relative survival prognosis is such these people have passed end first. Pancreatic cancer how staging works healthline. Pancreatic cancer low survival rates ncbi nih. After you're diagnosed with pancreatic cancer, your doctor will work to identify stage 2b this advanced of cancer means the tumor is growing in 2a, nearby tissue but does not involve blood vessels or l
Просмотров: 57 Tedfri Teff
In this video, CancerBro will explain the treatment for non-metastatic pancreatic cancer. Also, read more about Non-metastatic pancreatic cancer treatment explained by CancerBro. https://www.cancerbro.com/pancreatic-cancer-treatment/ Video Transcript: Now we will discuss the resectability of the pancreatic tumor, depending upon the extent of tumor. Tumor located within the pancreas, without extension to adjacent structutes, is considered to be resectable. This figure shows a resectable tumor located in the head of pancreas. Similarly, this is a resectable tumor located in the tail of pancreas. A tumor located in the head of the pancreas, that extends to involve the duodenum, is also considered to be resectable. Similarly, tumors arising from the tail of pancreas, that involve the spleen, left kidney, or left suprarenal gland, may also be resected. Superior mesenteric vein involvement maybe considered resectable, boderline resectable or unresectable, depending upon the extent of arterial involvement. Similarly, involvement of portal vein maybe considered resectable, borderline resectable or unresectable, depending upon the extent of arterial involvement. Infiltration of tumor into common hepatic artery only, is borderline resectable in most of the cases. Infiltration of tumor into the superior mesentric artery maybe considered borderline resectable or unresectable, depending upon the extent of arterial involvement. Celiac artery involvement may also be borderline resectable or unresectable, depending upon the extent of arterial involvement. Now we will discuss the treatment for all the three, that is resectable, borderline resectable, and unresectable disease. Surgery is the treatment of choice of resectable disease, but chemotherapy may be added rarely for some high risk patients. For borderline resectable patients, chemotherapy with or without radiotherapy is used, and then the decision for surgery is taken, depending upon the response to treatment. And for unresectable patients, chemotherapy is the treatment of choice, and radiotherapy maybe used very rarely. The final decision is taken by the oncologist, on an individual patient basis, depending upon the performance status of the patient and exact stage of the disease. About CancerBro - Cancer bro is a team of young, compassionate, highly qualified doctors and engineers who choose to look beyond themselves and help the society. Spreading cancer awareness is the objective which will be fulfilled by three facets of education, information and support. Combating any problem starts with awareness and information, with this approach we have built an impeccable information and educational channel. Inclusion of animated videos, expert blogs, articles and open contribution from various doctors, experts and even patients makes our website highly reliable. Visit CancerBro and become an active part of our cancer support community - http://www.cancerbro.com/ Follow our social media channels to get daily health tips and cancer awareness stuff from prevention to facts & figures related to cancer. Facebook - https://www.facebook.com/officialcancerbro Instagram - https://www.instagram.com/official_cancerbro Twitter - https://twitter.com/cancer_bro/
Просмотров: 7 CancerBro
3rd Gastrointestinal Cancer Conference Focus on pancreatic and biliary Cancer - Under the auspices of EORTC. Session 7: Borderline Resectable Pancreatic Cancer Chairs: Theo Ruers (The Netherlands), Thomas T. W. Seufferlein (Germany) Discussion
Просмотров: 744 oncoletter
Davendra Sohal, MD, MPH, Department of Hematology and Medical Oncology, Cleveland Clinic, discusses an ongoing study exploring mFOLFIRINOX versus gemcitabine and nab-paclitaxel (Abraxane) in patients with resectable pancreatic adenocarcinoma.
Просмотров: 79 OncLiveTV